ArticleCancer2010
Methadone initiation and rotation in the outpatient setting for patients with cancer pain.
Article in Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06940570 (A Randomized Single Center Trial to Determine the Efficacy of Methadone as a First Line Agent in the Reduction and Treatment of Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Single Center Trial to Determine the Efficacy of Methadone as a First Line Agent in the Reduction and Treatment of Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Adult cancer pain.Journal of the National Comprehensive Cancer Network : JNCCN · 2013Guideline
- Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- Trial
- Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.The oncologist · 2016Trial
- Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.Anesthesiology · 2015Trial
- The opioid rotation ratio of hydrocodone to strong opioids in cancer patients.The oncologist · 2014Trial
- Article
- Clinical Presentation and Management of Malignant Psoas Syndrome: A Scoping Review of Case Reports and Case Series.Cureus · 2023Article
- Methadone switching for refractory cancer pain.BMC palliative care · 2022Article
- Methadone as First-line Opioid for the Management of Cancer Pain.The oncologist · 2022Article
- First-line methadone for cancer pain: titration time analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- The role of methadone in cancer-induced bone pain: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.Journal of cancer research and clinical oncology · 2021Article
- CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.Frontiers in genetics · 2021Review
- Methadone for Pain Management: A Pharmacotherapeutic Review.CNS drugs · 2020Review
- Review
- Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.CNS oncology · 2018Article
- Practical Pharmacology of Methadone: A Long-acting Opioid.Indian journal of palliative care · 2018Review
- Methadone for Pain Management: Past, Present and Future.Indian journal of palliative care · 2018Review
- Practical Guide for Using Methadone in Pain and Palliative Care Practice.Indian journal of palliative care · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMethadone is an effective and inexpensive opioid for cancer pain treatment. It has been reported as difficult to use in the outpatient setting because of its variable relative potency and long half-life. The purpose of this study was to determine the outcome of methadone initiation or rotation for cancer pain treatment in outpatient settings.
methodsChart review was done of 189 consecutive patients who underwent methadone initiation or rotation at the authors' palliative care outpatient center. Data were collected regarding demographic and clinical characteristics, symptoms, and opioid side effects at baseline and for 2 follow-up visits (F1, F2). Failure was defined as methadone discontinuation by the palliative care physician or patient's hospitalization for uncontrolled pain or methadone-related side effects at F1.
resultsOne hundred (53%) initiations and 89 (47%) rotations were conducted. Success rates for methadone initiation and rotation were 82 of 89 (92%) and 85 of 100 (84%), respectively. Mean (standard deviation) age was 60 (11) years. One hundred (53%) patients were women, 138 (73%) were white, and 182 (96%) had solid cancers. The main reason for rotation was pain (65 of 89 patients, 47%). Median (interquartile range, IQR) pain scores (Edmonton Symptom Assessment Scale/0-10) were 6 (5-8), 4 (3-6), and 3 (2-5) at baseline, F1, and F2, respectively (P < .0001). Median (IQR) daily methadone dose for initiation and rotation was 10 (5-15) mg and 15 (10-30) mg at F1 (P < .0001) and 10 (8-15) mg and 18 (10-30) mg at F2 (P < .0001), respectively. Constipation and nausea improved (P < .005) after initiation/rotation to methadone. Frequency of sedation, hallucinations, myoclonus, and delirium did not increase after initiation/rotation to methadone.
conclusionsOutpatient methadone initiation and rotation for cancer pain treatment were safe, with high success rates and low side effect profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.